Clinical Trial Categories
Breast Cancer Trials
AL-TNBC-01
Avavilable at 13 locations
TENACITY: A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer
STAR 14059
Avavilable at 1 location
Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
USOR 17079
Avavilable at 7 locations
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
USOR 17188
Avavilable at 6 locations
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
USOR 17194
Avavilable at 1 location
A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination with Palbociclib in Women With Advanced or Metastatic ER- Positive and HER2-Negative Breast Cancer
USOR 19054
Avavilable at 15 locations
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
USOR 19105
Avavilable at 15 locations
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Gdc-0077 Plus Palbociclib And Fulvestrant Versus Placebo Plus Palbociclib And Fulvestrant In Patients With Pik3ca-Mutant, Horomone Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer
USOR 19226
Avavilable at 15 locations
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
USOR 20210
Avavilable at 12 locations
Breast Cancer Index (BCI) Registry Study
USOR 20431
Avavilable at 4 locations
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
